Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification

Modeling and simulation of drug disposition has emerged as an important tool in drug development, clinical study design and regulatory review, and the number of physiologically based pharmacokinetic (PBPK) modeling related publications and regulatory submissions have risen dramatically in recent years. However, the extent of use of PBPK modeling by researchers, and the public availability of models has not been systematically evaluated. This review evaluates PBPK-related publications to 1) identify the common applications of PBPK modeling; 2) determine ways in which models are developed; 3) establish how model quality is assessed; and 4) provide a list of publically available PBPK models for sensitive P450 and transporter substrates as well as selective inhibitors and inducers. PubMed searches were conducted using the terms “PBPK” and “physiologically based pharmacokinetic model” to collect published models. Only papers on PBPK modeling of pharmaceutical agents in humans published in English between 2008 and May 2015 were reviewed. A total of 366 PBPK-related articles met the search criteria, with the number of articles published per year rising steadily. Published models were most commonly used for drug-drug interaction predictions (28%), followed by interindividual variability and general clinical pharmacokinetic predictions (23%), formulation or absorption modeling (12%), and predicting age-related changes in pharmacokinetics and disposition (10%). In total, 106 models of sensitive substrates, inhibitors, and inducers were identified. An in-depth analysis of the model development and verification revealed a lack of consistency in model development and quality assessment practices, demonstrating a need for development of best-practice guidelines.

[1]  P. Neuvonen,et al.  Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions , 2014, Clinical pharmacology and therapeutics.

[2]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[3]  Harvey J Clewell,et al.  Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  M Rowland,et al.  The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[5]  A Rostami-Hodjegan,et al.  Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.

[6]  Filippos Kesisoglou,et al.  Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Tristan S. Maurer,et al.  A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.

[8]  S. Yeleswaram,et al.  Predicting Drug–Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib , 2015, Clinical pharmacology and therapeutics.

[9]  Magang Shou,et al.  Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator , 2009, Drug Metabolism and Disposition.

[10]  Daniel Röshammar,et al.  In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.

[11]  Prasad S. Dhurjati,et al.  Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption , 2012, Adv. Bioinformatics.

[12]  Diansong Zhou,et al.  Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents , 2014, Biopharmaceutics & drug disposition.

[13]  Filippos Kesisoglou,et al.  Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  Shiew-Mei Huang,et al.  Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study , 2009, Journal of clinical pharmacology.

[15]  Masoud Jamei,et al.  Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model , 2015, Front. Immunol..

[16]  William J. Jusko,et al.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model , 2015, Pharmaceutical Research.

[17]  Guidance for Industry Clinical Pharmacogenomics : Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling , 2013 .

[18]  Sebastian Polak,et al.  Assessment of inter-individual variability in predicted phenytoin clearance , 2009, European Journal of Clinical Pharmacology.

[19]  Ying-Hong Wang,et al.  Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.

[20]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[21]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[22]  M. Jamei,et al.  A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.

[23]  Sebastian Polak,et al.  Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Shiew-Mei Huang,et al.  Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[25]  L. Kuepfer,et al.  Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.

[26]  R. Obach,et al.  DMD054031 1975..1993 , 2013 .

[27]  Shiew-Mei Huang,et al.  Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions , 2014, Pharmaceutical Research.

[28]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[29]  Stephen D. Hall,et al.  Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model , 2015, Drug Metabolism and Disposition.

[30]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[31]  Ping Zhao,et al.  Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. , 2014, British journal of clinical pharmacology.

[32]  L. Berezhkovskiy,et al.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.

[33]  Ghanashyam Joshi,et al.  Have physiologically-based pharmacokinetic models delivered? , 2011, Expert opinion on drug metabolism & toxicology.

[34]  Jennifer B Dressman,et al.  Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  L Zhang,et al.  Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.

[36]  Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products , 2012 .

[37]  N. Djebli,et al.  Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics , 2015, Drug Metabolism and Disposition.

[38]  Hugh A. Barton,et al.  Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human , 2014, Drug Metabolism and Disposition.

[39]  John Crison,et al.  Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling. , 2012, Therapeutic delivery.

[40]  Brian Tomlinson,et al.  Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition , 2013, The AAPS Journal.

[41]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[42]  Sara K Quinney,et al.  Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.

[43]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[44]  Tycho Heimbach,et al.  A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy , 2013, The AAPS Journal.

[45]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[46]  K. Pang,et al.  THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.

[47]  Masoud Jamei,et al.  Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. , 2013, Journal of pharmaceutical sciences.

[48]  Ping Wang,et al.  A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. , 2011, Drug metabolism and pharmacokinetics.

[49]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[50]  N. Wood,et al.  Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use , 2011, Antimicrobial Agents and Chemotherapy.

[51]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[52]  Malcolm Rowland,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.

[53]  M Jamei,et al.  Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. , 2012, Current drug metabolism.

[54]  Amin Rostami-Hodjegan,et al.  Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. , 2012, Current drug metabolism.

[55]  Amin Rostami-Hodjegan,et al.  Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure , 2013, European Journal of Clinical Pharmacology.

[56]  N. Oberlies,et al.  Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction , 2014, CPT: pharmacometrics & systems pharmacology.

[57]  Y. Sugiyama,et al.  Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.

[58]  Chuang Lu,et al.  Assessment of cytochrome P450‐mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation , 2014, Biopharmaceutics & drug disposition.

[59]  Dae-Duk Kim,et al.  In vitro–in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications , 2014, Drug development and industrial pharmacy.

[60]  D. Thakker,et al.  A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children , 2014, Clinical Pharmacokinetics.

[61]  Maurice Dickins,et al.  Maraviroc: in vitro assessment of drug-drug interaction potential. , 2008, British journal of clinical pharmacology.

[62]  Patrick Poulin,et al.  A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design. , 2015, Journal of pharmaceutical sciences.

[63]  Harvey J. Clewell,et al.  A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair , 2012, Drug Metabolism and Disposition.

[64]  Jianghong Fan,et al.  PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.

[65]  B. Feng,et al.  Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.

[66]  Ping Zhao,et al.  Dealing with the complex drug-drug interactions: towards mechanistic models. , 2015, Biopharmaceutics & drug disposition.

[67]  Suman Sen,et al.  Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects , 2013, Journal of clinical pharmacology.

[68]  Denis Duboule,et al.  Contents , 2015, Mechanisms of Development.

[69]  Jennifer E Sager,et al.  Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[70]  Hugh A Barton,et al.  Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.

[71]  Masahiro Iwaki,et al.  Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients , 2014, The AAPS Journal.

[72]  Thomas Singer,et al.  Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants , 2011, Clinical pharmacokinetics.

[73]  A. D. Rodrigues,et al.  Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide , 2015, Drug Metabolism and Disposition.

[74]  Aleksandra Galetin,et al.  Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. , 2014, Methods in molecular biology.

[75]  Benoit Blanchet,et al.  Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach , 2014, The AAPS Journal.

[76]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[77]  Anna M. Wu,et al.  A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[78]  Ping Xu,et al.  A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. , 2013, Journal of pharmaceutical sciences.

[79]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .

[80]  D. Leahy,et al.  Progress in simulation modelling for pharmacokinetics. , 2003, Current topics in medicinal chemistry.

[81]  Y. Zhang,et al.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[82]  Erik Sjögren,et al.  In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[83]  Rui Chen,et al.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling , 2012, Acta Pharmacologica Sinica.

[84]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[85]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[86]  S D Hall,et al.  An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[87]  Amin Rostami-Hodjegan,et al.  Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[88]  Jian Lin,et al.  Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin , 2013, Drug Metabolism and Disposition.

[89]  Nikolaos Tsamandouras,et al.  Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk , 2014, Pharmaceutical Research.

[90]  U. Christians,et al.  Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content , 2013, CPT: pharmacometrics & systems pharmacology.

[91]  Li Liu,et al.  Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model , 2015, Clinical Pharmacokinetics.

[92]  M. Sheffer,et al.  CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .

[93]  Malcolm Rowland,et al.  Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[94]  S. Hall,et al.  Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[95]  J. Gallo,et al.  Multiscale Design of Cell-Type–Specific Pharmacokinetic/Pharmacodynamic Models for Personalized Medicine: Application to Temozolomide in Brain Tumors , 2014, CPT: pharmacometrics & systems pharmacology.

[96]  Atsushi Kambayashi,et al.  Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[97]  K. Pang,et al.  Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.

[98]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION , 2005 .

[99]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[100]  Yuan Chen,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone , 2015, Drug Metabolism and Disposition.

[101]  S-M Huang,et al.  Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials , 2012, Clinical pharmacology and therapeutics.

[102]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[103]  Thuy Tran,et al.  Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development , 2013, Drug Metabolism and Disposition.

[104]  William J. Jusko,et al.  Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[105]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[106]  Yuichi Sugiyama,et al.  Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes , 2013, Drug Metabolism and Disposition.

[107]  Wilhelm Huisinga,et al.  Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[108]  Jashvant D Unadkat,et al.  Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. , 2014, Biochemical pharmacology.

[109]  He Lian,et al.  Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. , 2013, International journal of pharmaceutics.

[110]  Hannah M. Jones,et al.  Modelling and PBPK Simulation in Drug Discovery , 2009, The AAPS Journal.

[111]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[112]  Paolo Vicini,et al.  Physiologically based pharmacokinetic model of midazolam disposition during pregnancy , 2008, 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[113]  François Bouzom,et al.  Comparing translational population‐PBPK modelling of brain microdialysis with bottom‐up prediction of brain‐to‐plasma distribution in rat and human , 2014, Biopharmaceutics & drug disposition.

[114]  Wojciech Krzyzanski,et al.  Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies , 2014, The AAPS Journal.

[115]  Andrea N Edginton,et al.  Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition , 2014, Clinical Pharmacokinetics.

[116]  Markus Luster,et al.  Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model , 2010, Journal of Nuclear Medicine.

[117]  Stefan Willmann,et al.  Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling , 2009, Clinical pharmacokinetics.

[118]  Li Liu,et al.  A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[119]  Fahima Nekka,et al.  Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.

[120]  Wilhelm Huisinga,et al.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[121]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[122]  Hugh A. Barton,et al.  A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[123]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[124]  Lu Gaohua,et al.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. , 2012, British journal of clinical pharmacology.

[125]  M Jamei,et al.  Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.

[126]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[127]  Jian Lin,et al.  Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide , 2014, The AAPS Journal.

[128]  Yves Bertrand,et al.  Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model , 2010, Pharmaceutical Research.

[129]  Masoud Jamei,et al.  Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. , 2013, Journal of pharmaceutical sciences.

[130]  Sieto Bosgra,et al.  Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[131]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[132]  Thierry Lavé,et al.  Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.

[133]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[134]  Tycho Heimbach,et al.  Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data , 2012, The AAPS Journal.

[135]  Khaled Abduljalil,et al.  Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations , 2014, Drug Metabolism and Disposition.

[136]  Marco Siccardi,et al.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV , 2015, Clinical Pharmacokinetics.

[137]  Amin Rostami-Hodjegan,et al.  Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! , 2012, Biopharmaceutics & drug disposition.

[138]  P. Zhao,et al.  A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction , 2012, CPT: pharmacometrics & systems pharmacology.

[139]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[140]  I Zineh,et al.  Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy , 2014, Clinical pharmacology and therapeutics.

[141]  Athanassios Iliadis,et al.  Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[142]  Yves Bertrand,et al.  Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model , 2010, Pharmaceutical Research.

[143]  Masoud Jamei,et al.  Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model , 2014, The AAPS Journal.

[144]  Marjo Yliperttula,et al.  Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier , 2013, Pharmaceutical Research.

[145]  Manuela Pavan,et al.  Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. , 2013, Toxicology letters.

[146]  William J. Jusko,et al.  Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[147]  Lei Zhang,et al.  Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations , 2014, Clinical Pharmacokinetics.

[148]  William J. Jusko,et al.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[149]  K Rowland-Yeo,et al.  Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine , 2013, CPT: pharmacometrics & systems pharmacology.

[150]  U. Hofmann,et al.  A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. , 2015, Journal of pharmaceutical sciences.

[151]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[152]  K. Sandy Pang,et al.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[153]  Charles A Timchalk,et al.  A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. , 2013, Regulatory toxicology and pharmacology : RTP.

[154]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[155]  Emmanuel Scheubel,et al.  Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin , 2014, The AAPS Journal.

[156]  Y. Zhang,et al.  Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model , 2015, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[157]  John A Wagner,et al.  Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go? , 2011, Journal of clinical pharmacology.

[158]  J. Kindt,et al.  Understanding pharmacokinetic food effects using molecular dynamics simulation coupled with physiologically based pharmacokinetic modeling , 2012, Biopharmaceutics & drug disposition.

[159]  A. Vinks,et al.  The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women , 2013, CPT: pharmacometrics & systems pharmacology.

[160]  Leon Aarons,et al.  A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children , 2014, Pharmaceutical Research.

[161]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.

[162]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[163]  Bernd Meibohm,et al.  Tools for predicting the PK/PD of therapeutic proteins , 2015, Expert opinion on drug metabolism & toxicology.

[164]  Hefei Zhang,et al.  Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect , 2014, AAPS PharmSciTech.

[165]  Kannan Krishnan,et al.  Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms , 2012, Journal of toxicology.

[166]  Diansong Zhou,et al.  Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects , 2015, Journal of clinical pharmacology.

[167]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.

[168]  David A Mankoff,et al.  Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study , 2015, Drug Metabolism and Disposition.

[169]  Zhe-Yi Hu,et al.  Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate , 2014, British journal of pharmacology.

[170]  Hefei Zhang,et al.  Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound , 2013, AAPS PharmSciTech.

[171]  Ping Zhao,et al.  A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women , 2013, Drug Metabolism and Disposition.

[172]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[173]  H. E. Buist,et al.  Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .

[174]  J R Gillette FACTORS AFFECTING DRUG METABOLISM , 1971, Annals of the New York Academy of Sciences.

[175]  Marco Siccardi,et al.  Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach , 2013, Clinical Pharmacokinetics.